IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 253 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $120,279 | -86.2% | 26,435 | -81.5% | 0.00% | – |
Q1 2023 | $873,809 | -89.6% | 143,013 | -89.1% | 0.00% | -100.0% |
Q4 2022 | $8,378,000 | -65.2% | 1,311,260 | -47.8% | 0.00% | -66.7% |
Q3 2022 | $24,064,000 | -27.6% | 2,512,167 | -16.5% | 0.01% | -25.0% |
Q2 2022 | $33,231,000 | -20.9% | 3,010,014 | +19.4% | 0.01% | 0.0% |
Q1 2022 | $41,985,000 | -11.0% | 2,521,505 | +2.1% | 0.01% | -7.7% |
Q4 2021 | $47,150,000 | -12.0% | 2,469,709 | +13.7% | 0.01% | -23.5% |
Q3 2021 | $53,577,000 | +60.0% | 2,171,600 | +68.8% | 0.02% | +70.0% |
Q2 2021 | $33,476,000 | +132.7% | 1,286,447 | +183.2% | 0.01% | +100.0% |
Q1 2021 | $14,384,000 | -8.2% | 454,323 | +34.6% | 0.01% | -16.7% |
Q4 2020 | $15,671,000 | +93.8% | 337,508 | +37.4% | 0.01% | +100.0% |
Q3 2020 | $8,087,000 | +2669.5% | 245,665 | +2155.9% | 0.00% | – |
Q2 2020 | $292,000 | +29.8% | 10,890 | +19.9% | 0.00% | – |
Q1 2020 | $225,000 | -81.3% | 9,080 | -87.2% | 0.00% | -100.0% |
Q1 2018 | $1,203,000 | – | 71,201 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |